celecoxib has been researched along with gemcitabine in 26 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 17 (65.38) | 29.6817 |
| 2010's | 9 (34.62) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benfenati, E; Raska, I; Toropov, AA; Toropova, AP | 1 |
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Crane, CH; Janjan, NA; Mason, K; Milas, L | 1 |
| Hada, M; Mizutari, K | 1 |
| Ali, S; El-Rayes, BF; Philip, PA; Sarkar, FH | 1 |
| Campbell, C; Harvey, H; Kerr, S; Legore, K; Lipton, A; Witters, L | 1 |
| Abbruzzese, JL; Du, M; Lenzi, R; Plunkett, W; Wolff, R; Xiong, HQ | 1 |
| Adsay, V; El-Rayes, BF; Ferris, AM; Heilbrun, LK; Philip, PA; Shields, AF; Vaishampayan, U; Venkatramanamoorthy, R; Zalupski, MM | 1 |
| Wang, XP; Wu, K; Xu, G; Zhao, S | 1 |
| Amoroso, V; Ferrari, V; Grisanti, S; Marini, G; Marpicati, P; Nodari, F; Rangoni, G; Simoncini, E; Strina, C; Tiberio, GA; Valcamonico, F; Vassalli, L | 1 |
| Hada, M; Horiuchi, T | 1 |
| Hada, M; Horiuchi, T; Shinji, H | 1 |
| Altorki, NK; Bonomi, P; Fayyad, R; Hariharan, S; Hart, LL; Keresztes, RS; Lilenbaum, R; Morrison, ME; Socinski, MA | 1 |
| Antognoli, S; Berardi, R; Carbonari, G; Cascinu, S; Giampieri, R; Mariani, C; Pierantoni, C; Scartozzi, M; Silva, RR; Squadroni, M; Verdecchia, L | 1 |
| Bedor, M; Edelman, MJ; Gajra, A; Green, MJ; Hodgson, L; Jewell, S; Kratzke, RA; Masters, GA; Mauer, AM; Morrison, C; Vokes, EE; Wang, X; Watson, D | 1 |
| Alvarez, I; Burris, H; Chow, S; Dragovich, T; Gordon, M; Green, S; Loehrer, P; Obregon, Y; Stratton, S; Von Hoff, DD | 1 |
| Arefayene, M; Basu, GD; Bradley, JM; De Petris, G; Mukherjee, P; Skaar, T; Subramani, DB; Tinder, TL | 1 |
| Mayo, MS; Smith, HJ; Watkins, JF; Williamson, SK | 1 |
| Bernard, C; Grushka, JR; Laberge, JM; Mueller, C; Nguyen, VH; Puligandla, PS; Roessingh, Ade B; Ryckman, J; St Vil, D; Walton, JM | 1 |
| Ali, S; Campbell-Baird, C; Harvey, H; Lipton, A; Witters, L | 1 |
| Brand, RE; Singh, SV; Stan, SD | 1 |
| Christenson, R; Edelman, MJ; Hodgson, L; Jewell, S; Kratzke, R; Vokes, E; Wang, X | 1 |
| Cheng, G; Dwinell, MB; Kalyanaraman, B; McAllister, D; Tsai, S; Zielonka, J | 1 |
| Avola, R; Cardile, V; Eleonora Graziano, AC; Pistarà, V; Rescifina, A; Stancanelli, R; Surdo, E; Tommasini, S; Ventura, CA | 1 |
| Bai, X; Chen, Q; Chen, Y; Dang, X; Fu, Q; Liang, T; Lou, Y; Wang, J; Wei, T; Yang, J; Ye, M; Zhang, J; Zhang, Q; Zhang, X | 1 |
4 review(s) available for celecoxib and gemcitabine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Initial experience combining cyclooxygenase-2 inhibition with chemoradiation for locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Clinical Trials, Phase I as Topic; Combined Modality Therapy; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Deoxycytidine; Gemcitabine; Humans; Isoenzymes; Membrane Proteins; Pancreatic Neoplasms; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Radiation-Sensitizing Agents; Sulfonamides | 2003 |
Spindle epithelial tumor with thymus-like elements of the thyroid: a multi-institutional case series and review of the literature.
Topics: Abscess; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma; Celecoxib; Child; Child, Preschool; Choristoma; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Deoxycytidine; Diagnostic Errors; Doxorubicin; Etoposide; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Male; Pyrazoles; Radiography; Sulfonamides; Teratoma; Thalidomide; Thymus Gland; Thyroid Neoplasms; Thyroidectomy | 2009 |
Chemoprevention strategies for pancreatic cancer.
Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; beta Carotene; Camellia sinensis; Celecoxib; Cell Transformation, Neoplastic; Chemoprevention; Curcumin; Cyclooxygenase 2 Inhibitors; Deoxycytidine; Disease Models, Animal; Down-Regulation; Drug Synergism; Gemcitabine; Humans; Isothiocyanates; Pancreatic Neoplasms; Phototherapy; Pyrazoles; Sulfonamides; Tea; Vitamin D; Vitamin E | 2010 |
11 trial(s) available for celecoxib and gemcitabine
| Article | Year |
|---|---|
Gemcitabine/Irinotecan/celecoxib in pancreatic cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Celecoxib; Cyclooxygenase Inhibitors; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Neutropenia; Pancreatic Neoplasms; Pyrazoles; Sulfonamides; Time Factors; Treatment Outcome | 2004 |
A pharmacological study of celecoxib and gemcitabine in patients with advanced pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Deoxycytidine; Drug Administration Schedule; Drug Interactions; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Pancreatic Neoplasms; Pyrazoles; Sulfonamides; Treatment Outcome | 2005 |
A phase II study of celecoxib, gemcitabine, and cisplatin in advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Cisplatin; Cyclooxygenase Inhibitors; Deoxycytidine; Female; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Pancreatic Neoplasms; Peritoneal Neoplasms; Pyrazoles; Sulfonamides; Survival Analysis | 2005 |
Gemcitabine plus celecoxib (GECO) in advanced pancreatic cancer: a phase II trial.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Pancreatic Neoplasms; Pyrazoles; Sulfonamides; Survival Analysis; Treatment Outcome | 2006 |
Randomized phase II trial of docetaxel/irinotecan and gemcitabine/irinotecan with or without celecoxib in the second-line treatment of non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cyclooxygenase Inhibitors; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Pyrazoles; Sulfonamides; Survival Analysis; Taxoids; Treatment Outcome | 2006 |
COX-2 and NF-KB overexpression is common in pancreatic cancer but does not predict for COX-2 inhibitors activity in combination with gemcitabine and oxaliplatin.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Deoxycytidine; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Male; Middle Aged; NF-kappa B; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Patient Selection; Predictive Value of Tests; Pyrazoles; Sulfonamides; Treatment Outcome | 2007 |
Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Eicosanoids; Female; Gemcitabine; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Hydroxyurea; Immunohistochemistry; Lipoxygenase Inhibitors; Logistic Models; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Prognosis; Prospective Studies; Pyrazoles; Sulfonamides; Up-Regulation | 2008 |
Gemcitabine plus celecoxib in patients with advanced or metastatic pancreatic adenocarcinoma: results of a phase II trial.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Pyrazoles; Sulfonamides; Survival Analysis; Vascular Endothelial Growth Factor A | 2008 |
Gemcitabine, irinotecan and celecoxib in patients with biliary cancer.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Camptothecin; Celecoxib; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Pyrazoles; Sulfonamides; Thrombocytopenia; Treatment Outcome | 2009 |
Phase II trial of gemcitabine, irinotecan, and celecoxib in patients with advanced pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Celecoxib; Cyclooxygenase 2 Inhibitors; Deoxycytidine; Drug Administration Schedule; Drug Therapy, Combination; Female; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Pyrazoles; Sulfonamides; Treatment Outcome | 2010 |
Serum vascular endothelial growth factor and COX-2/5-LOX inhibition in advanced non-small cell lung cancer: Cancer and Leukemia Group B 150304.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arachidonate 5-Lipoxygenase; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Celecoxib; Cyclooxygenase 2; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Prospective Studies; Pyrazoles; Sulfonamides; Vascular Endothelial Growth Factor A | 2011 |
11 other study(ies) available for celecoxib and gemcitabine
| Article | Year |
|---|---|
QSPR modeling of octanol/water partition coefficient of antineoplastic agents by balance of correlations.
Topics: Antineoplastic Agents; Models, Chemical; Octanols; Quantitative Structure-Activity Relationship; Water | 2010 |
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
[A case of advanced pancreatic cancer with remarkable response to thalidomide, celecoxib and gemcitabine].
Topics: Administration, Oral; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Infusions, Intravenous; Isoenzymes; Male; Membrane Proteins; Pancreatic Neoplasms; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Thalidomide | 2004 |
Cyclooxygenase-2-dependent and -independent effects of celecoxib in pancreatic cancer cell lines.
Topics: Apoptosis; Celecoxib; Cell Line, Tumor; Cell Survival; Cyclooxygenase 2; Deoxycytidine; Gemcitabine; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Membrane Proteins; NF-kappa B; Pancreatic Neoplasms; Prostaglandin-Endoperoxide Synthases; Pyrazoles; RNA, Messenger; Sulfonamides | 2004 |
[Enhancing effects of celecoxib on the growth inhibition of pancreatic carcinoma by gemcitabine treatment].
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Celecoxib; Cell Cycle; Cyclooxygenase Inhibitors; Deoxycytidine; Drug Synergism; Female; Gemcitabine; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Pancreatic Neoplasms; Pyrazoles; Sulfonamides; Tumor Cells, Cultured | 2005 |
[A case report of chemotherapy with thalidomide, celecoxib and gemcitabine in the treatment of patients with brain metastases from lung cancer].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Celecoxib; Combined Modality Therapy; Cranial Irradiation; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Lung Neoplasms; Male; Pyrazoles; Sulfonamides; Thalidomide | 2005 |
[A case report of unresectable gallbladder cancer that responded remarkably to the combination of thalidomide, celecoxib, and gemcitabine].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Deoxycytidine; Drug Administration Schedule; Gallbladder Neoplasms; Gemcitabine; Humans; Liver Neoplasms; Male; Neoplasm Invasiveness; Peritoneal Neoplasms; Prognosis; Pyrazoles; Remission Induction; Sulfonamides; Thalidomide | 2006 |
Progression of pancreatic adenocarcinoma is significantly impeded with a combination of vaccine and COX-2 inhibition.
Topics: Adenocarcinoma; Animals; Antibodies; Cancer Vaccines; Carcinoma, Pancreatic Ductal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Deoxycytidine; Disease Progression; Drug Evaluation, Preclinical; Drug Therapy, Combination; Gemcitabine; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Mice; Mice, Transgenic; Mucin-1; Pancreatic Neoplasms; Pyrazoles; Sulfonamides; Vaccines, Subunit | 2009 |
Profiling and targeting of cellular bioenergetics: inhibition of pancreatic cancer cell proliferation.
Topics: Adenosine Triphosphate; Antineoplastic Agents; Celecoxib; Cell Culture Techniques; Cell Growth Processes; Cell Line, Tumor; Deoxycytidine; Deoxyglucose; Doxorubicin; Energy Metabolism; Gemcitabine; Glycolysis; Humans; Hydrogen; Metformin; Mitochondria; Oxygen Consumption; Pancreatic Neoplasms; Pyrazoles; Sulfonamides | 2014 |
Gemcitabine anticancer activity enhancement by water soluble celecoxib/sulfobutyl ether-β-cyclodextrin inclusion complex.
Topics: A549 Cells; Antineoplastic Agents; beta-Cyclodextrins; Celecoxib; Deoxycytidine; Drug Compounding; Drug Synergism; Gemcitabine; Humans; Molecular Dynamics Simulation; Powders; Solubility; Water | 2019 |
Tumour cell-derived debris and IgG synergistically promote metastasis of pancreatic cancer by inducing inflammation via tumour-associated macrophages.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Celecoxib; Cell Line, Tumor; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Immunoglobulin G; Inflammation; Interleukin-1beta; Macrophages; Male; Mice; Mice, Inbred C57BL; Neoplasm Metastasis; Pancreatic Neoplasms; THP-1 Cells; Xenograft Model Antitumor Assays | 2019 |